News Headlines Article

FDA OKs four gene-sequencing devices targeting cystic fibrosis
Modern Healthcare

The Food and Drug Administration cleared four gene-sequencing devices developed by San Diego-based Illumina that are expected to improve the screening and diagnosis of patients with cystic fibrosis.

Two of the newly cleared devices can detect changes in a patient’s DNA that may result in cystic fibrosis, a genetic disorder that affects about 30,000 children and adults in the U.S. The average life span for patients who are diagnosed with cystic fibrosis is about 37 years old.